Skip to main navigation

Top Bar Nav

Contact Us

Social Icons

linkedin twitter

About Nav

About

Pioneering Pathways

Pioneering Pathways

Medicines Nav

Medicines

Science Nav

Science

Our Purpose Nav

Our Purpose

Our Stories

Our Stories

News Nav

News

IR Nav

Investors

Careers Nav

Careers

Home News Press Release Archive

Press Release Archive

News Nav

News
Press Release Archive
Events Archive
Our Stories

Media Contact

Kristin Bhavnani
Head of Global Corporate Communications
Jazz Pharmaceuticals plc

Send Email
Ireland: +353 1 637 2141
US: 215-867-4948

Press Release Archive

Year

Jazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

December 17, 2024

Jazz Pharmaceuticals Announces CEO Succession Plan

December 16, 2024

Jazz Pharmaceuticals to Showcase New Real-World Evidence Reinforcing Epidiolex® (cannabidiol) Benefits and Broad-Spectrum Efficacy in Treatment-Resistant Epilepsies at the American Epilepsy Society 2024 Annual Meeting

December 6, 2024

Jazz Pharmaceuticals Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Biliary Tract Cancers to Include zanidatamab-hrii (Ziihera®)

December 5, 2024

Jazz Pharmaceuticals Announces Ziihera® (zanidatamab-hrii) Investor Webcast on December 11, 2024

December 4, 2024

Jazz Pharmaceuticals to Present Advancements in Solid Tumors and Blood Cancer Research at San Antonio Breast Cancer Symposium and American Society of Hematology Annual Meeting

December 3, 2024

Jazz Pharmaceuticals Announces U.S. FDA Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)

November 20, 2024

Jazz Pharmaceuticals to Participate in Citi's 2024 Global Healthcare Conference

November 19, 2024

Jazz Pharmaceuticals Announces Third Quarter 2024 Financial Results

November 6, 2024

Jazz Pharmaceuticals Presents New Data at Psych Congress 2024 Confirming Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Benefits in Narcolepsy and Idiopathic Hypersomnia

October 31, 2024

Pagination

Current page 1
Page 2
Page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Page 9
…
Next page
Last page

Displaying 1 - 10 of 559

About Nav

About

Pioneering Pathways Nav

Pioneering Pathways

Medicines Nav

Medicines

Science Nav

Science

Our Purpose Nav

Our Purpose

Our Stories Nav

Our Stories

News Nav

News

Careers Nav

Careers

IR Nav

Investors

© 2024 Jazz Pharmaceuticals plc All Rights Reserved.

Legal Nav

Privacy Statement
Terms of Use
Social Media Global Guidelines
Cookie Policy
Sitemap